Seliciclib-D7

Seliciclib-D7 is a deuterated version of the drug Seliciclib, which is a cyclin-dependent kinase (CDK) inhibitor used in cancer therapy. CDKs are enzymes that regulate the cell cycle and their overexpression or malfunctioning can cause uncontrolled cell division leading to cancer. Seliciclib-D7 is a potent inhibitor of CDK2, CDK7, and CDK9, which are important targets in cancer treatment. It acts by binding to the ATP-binding site of these CDKs, thereby preventing their activity and halting the cell cycle progression. The deuterated form of Seliciclib-D7 is used in pharmacokinetic studies to determine the drug's metabolic fate, bioavailability and elimination rates. Deuterium is an isotope of hydrogen that has an additional neutron in its nucleus. The use of deuterium in drug development enables the creation of drugs that have enhanced stability, longer half-lives, and reduced toxicity. In the case of Seliciclib-D7, the deuterium labeled compound is used in drug metabolism studies to track the drug's metabolic products and their excretion rates. Seliciclib-D7 has been studied in pre-clinical and clinical trials for its potential as an anti-tumor agent. The drug has shown promising results in inducing cell cycle arrest and apoptosis in various cancer cell lines. However, further research is needed to determine its efficacy and safety in treating different types of cancer. Seliciclib-D7 is a valuable tool in drug development and cancer research, providing insights into the mechanisms of CDK inhibition and drug metabolism.